Epinephrine 1 is under clinical development by Bioprojet SCR and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Epinephrine 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epinephrine 1 overview

Epinephrine is under development for the treatment of anaphylaxis. The drug candidate acts by targeting alpha and beta-adrenergic receptors.

Bioprojet SCR overview

Bioprojet SCR (Bioprojet) is a drug development company that offers anapen, an auto-injector pen for the immediate treatment of anaphylactic shock, tiorfan, an intestinal anti-secretory drug for the treatment of acute diarrhoea and wakix, a histamine H3 receptor antagonist and agonist inverse for the treatment of drowsiness with or without cataplexy. Bioprojet develops drugs in the therapeutic areas of gastro enterology, cardiovascular, central nervous system, and other compounds in preclinical development. The company distributes its products to 70 countries in Europe, Africa, Asia and Latin America. Bioprojet is headquartered in Paris, Ile-de-France France.

For a complete picture of Epinephrine 1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.